Company Name: MyoKardia, Inc.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of precision medicines designed to treat rare cardiovascular diseases. The company’s initial focus is on developing therapies designed to treat hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
Ticker Symbol: MYOK (NASDAQ)
Company Website: www.myokardia.com
Headquarters: South San Francisco, CA